Rachel Park
Women's Health · Fountain Valley, CANPI 1275935009
Payments from drug & device makers
What this record shows
Pfizer accounts for 61.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $1,477 and has fallen 96.0% since, to $59 in 2024. Among women's health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $121.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Avion Pharmaceuticals$220
- Acella Pharmaceuticals, LLC$130
- Bayer$130
- Astellas Pharma US Inc$73
- Sumitomo Pharma America, Inc.$45
- plus $104 from 6 others
What the payments were for
- Consulting fees$1,08059%
- Food & beverage$74941%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $1,126 |
| Avion Pharmaceuticals | 1 | $220 |
| Acella Pharmaceuticals, LLC | 1 | $130 |
| Bayer | 1 | $130 |
| Astellas Pharma US Inc | 1 | $73 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| GSK | 1 | $26 |
| Lilly USA, LLC | 1 | $24 |
| IBSA Pharma Inc. | 1 | $15 |
| Evofem Biosciences, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Mayne Pharma Commercial LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,829 in reported general payments places this provider in the 90th percentile of 480 women's health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 29 | $2,145 |
| Clindamycin Phosphate | 14 | $962 |
Paid to pharmacies, not to this prescriber.
Other women's health in Fountain Valley
- Michelle TodescoFountain Valley$2K
- Barbara DehnMountain View$87K
- Zaruhi HarutyunyanWest Hollywood$55K
- Roberta MoradfarWest Hollywood$30K
- Patricia GeraghtyWalnut Creek$26K
- Katherine KetzStockton$26K
- Debbie BarishBerkeley$16K
- Raisa HowardEl Segundo$11K
- Mary FesselWoodland$8K
- Kay MorelandSanta Maria$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.